Testing zanubrutinib for antiphospholipid syndrome with low platelets
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This Phase 2 study tests zanubrutinib, a medicine for the immune system, to treat antiphospholipid syndrome when it causes very low platelet counts. It looks at safety and whether it can improve blood clotting problems and low platelets when prior steroid treatment didn’t work well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older
- You have been diagnosed with antiphospholipid syndrome
- Your steroid treatment (glucocorticoids) did not work well, could not be kept going, or you couldn’t tolerate it
- Your platelet count is very low (under 30 × 10^9/L)
- Your liver and kidney blood tests are not severely abnormal (ALT, AST, BUN, creatinine under 1.5× the lab’s upper limit)
- You can safely take part in the study (general health not too limited, heart function not too poor) and you can sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study looks at zanubrutinib, a new medication, in people with immune thrombocytopenia (ITP) whose low platelet count has lasted more than 3 months and has not responded to prior steroid and other treatments. It may help raise platelets and reduce bleeding risk when other therapies have not worked.
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
This study tests a new combination of two medicines—one that calms the immune system and one that helps your body make more platelets. It is for people with long-term ITP who have already tried other treatments and still have low platelet counts.
This study tests different doses of a drug called zanubrutinib (a BTK inhibitor) to find the best dose for adults with newly diagnosed ITP that hasn't been treated yet. It aims to see if this drug can safely boost platelet counts and reduce bleeding symptoms.
This study is testing a targeted medicine called zanubrutinib in people aged 80 and older who have chronic lymphocytic leukemia (CLL) that has not been treated yet. It aims to see if this medication can control the disease while being safe and manageable for older adults.
This trial tests a new drug called pirtobrutinib for people with immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it can help raise your platelet count and reduce bleeding risk.
Hear when a new Antiphospholipid Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.